Advances in understanding the pathogenesis of barrett's esophagus

Discovery Medicine

Volumn 17, Issue 91, 2014, Pages 7-14

  Clemons, Nicholas J ^a   Koh, Shze Yung ^a   Phillips, Wayne A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; INTERLEUKIN 1BETA; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX9;

ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CELL DIFFERENTIATION; DISEASE COURSE; DISEASE SURVEILLANCE; GENE EXPRESSION; HUMAN; PROTEIN EXPRESSION; RISK FACTOR; UPREGULATION; WNT SIGNALING PATHWAY; WOUND HEALING;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INTESTINAL MUCOSA; TRANSCRIPTION FACTORS;

EID: 84892719503     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Bhat S, Coleman HG, Yousef F, Johnston BT, Mcmanus DT, Gavin AT, Murray LJ. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 103(13):1049-1057, 2011.
2. Castillo D, Puig S, Iglesias M, Seoane A, De Bolos C, Munitiz V, Parrilla P, Comerma L, Poulsom R, Krishnadath KK, Grande L, Pera M. Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett's esophagus. J Gastrointest Surg 16(2):227-237; discussion 237, 2012.
3. Clemons NJ, Wang DH, Croagh D, Tikoo A, Fennell CM, Murone C, Scott AM, Watkins DN, Phillips WA. Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 303(12):G1335-G1346, 2012.
4. Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S, D'onofrio V, Lacchin T, Iaquinto G, Missale G, Ravelli P, Cestari R, Benedetti G, Macri G, Fiocca R, Munizzi F, Filiberti R. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 98(9):1931-1939, 2003.
5. Cook MB, Shaheen NJ, Anderson LA, Giffen C, Chow WH, Vaughan TL, Whiteman DC, Corley DA. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 142(4):744-753, 2012.
6. Corley DA, Mehtani K, Quesenberry C, Zhao W, De Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 145(2):312-9.e1, 2013.
7. Crane SJ, Locke GR, 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ. Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc 83(10):1087-1094, 2008.
8. Croagh D, Thomas RJ, Phillips WA, Kaur P. Esophageal stem cells - a review of their identification and characterization. Stem Cell Rev 4(4):261-268, 2008.
9. Demicco EG, Farris AB, 3rd, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 24(9):1177-1190, 2011.
10. Di Pietro M, Lao-Sirieix P, Boyle S, Cassidy A, Castillo D, Saadi A, Eskeland R, Fitzgerald RC. Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc Natl Acad Sci U S A 109(23):9077-9082, 2012.
11. Dunn LJ, Shenfine J, Griffin SM. Columnar metaplasia in the esophageal remnant after esophagectomy: a systematic review. Dis Esophagus, epub ahead of print, Nov. 13, 2013.
12. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, Mutoh H, Sugano K. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 38(1):14-22, 2003.
13. Edgren G, Adami HO, Weiderpass Vainio E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62(10):1406-1414, 2013.
14. Engel LS, Chow W-H, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95(18):1404-1413, 2003.
15. Estores D, Velanovich V. Barrett esophagus: epidemiology, pathogenesis, diagnosis, and management. Curr Probl Surg 50(5):192-226, 2013.
16. Fernandes ML, Seow A, Chan Y-H, Ho K-Y. Opposing trends in incidence of esophageal squamous cell carcinoma and adenocarcinoma in a multi-ethnic Asian country. Am J Gastroenterol 101(7):1430-1436, 2006.
17. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55(12):1810-1820, 2006.
18. Gatalica Z, Chen M, Snyder C, Mittal S, Lynch HT. Barrett's esophagus in the patients with familial adenomatous polyposis. Fam Cancer, epub ahead of print, Jun. 16, 2013.
19. Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg 258(1):82-88, 2013.
20. Gillen P, Keeling P, Byrne PJ, Healy M, O'moore RR, Hennessy TP. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg 75(6):540-543, 1988.
21. Hameeteman W, Tytgat GN, Houthoff HJ, Van Den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96(5 Pt 1):1249-1256, 1989.
22. Hamilton SR, Yardley JH. Regnerative of cardiac type mucosa and acquisition of Barrett mucosa after esophagogastrostomy. Gastroenterology 72(4 Pt 1):669-675, 1977.
23. Huo X, Zhang HY, Zhang XI, Lynch JP, Strauch ED, Wang JY, Melton SD, Genta RM, Wang DH, Spechler SJ, Souza RF. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 139(1):194-203, e191, 2010.
24. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119(6):1149-1158, 2013.
25. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365(15):1375-1383, 2011.
26. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 356(9247):2079-2085, 2000.
27. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55(1):16-25, 2006.
28. Kendall BJ, Macdonald GA, Hayward NK, Prins JB, O'Brien S, Whiteman DC. The risk of Barrett's esophagus associated with abdominal obesity in males and females. Int J Cancer 132(9):2192-2199, 2013.
29. Koak Y, Winslet M. Changing role of in vivo models in columnar-lined lower esophagus. Dis Esophagus 15(4):271-277, 2002.
30. Kong J, Crissey MA, Funakoshi S, Kreindler JL, Lynch JP. Ectopic Cdx2 expression in murine esophagus models an intermediate stage in the emergence of Barrett's esophagus. PloS one 6(4):e18280, 2011a.
31. Kong J, Crissey MA, Stairs DB, Sepulveda AR, Lynch JP. Cox2 and beta-catenin/T-cell factor signaling intestinalize human esophageal keratinocytes when cultured under organotypic conditions. Neoplasia 13(9):792-805, 2011b.
32. Kong J, Crissey MA, Sepulveda AR, Lynch JP. Math1/Atoh1 contributes to intestinalization of esophageal keratinocytes by inducing the expression of muc2 and keratin-20. Dig Dis Sci 57(4):845-857, 2012.
33. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma. N Engl J Med 340(11):825-831, 1999.
34. Li H, Walsh TN, O'Dowd G, Gillen P, Byrne PJ, Hennessy TP. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 115(2):176-181, 1994.
35. Litingtung Y, Lei L, Westphal H, Chiang C. Sonic hedgehog is essential to foregut development. Nat Genet 20(1):58-61, 1998.
36. Liu T, Zhang X, So CK, Wang S, Wang P, Yan L, Myers R, Chen Z, Patterson AP, Yang CS, Chen X. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28(2):488-496, 2007.
37. MacDonald CE, Wicks AC, Playford RJ. Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut 41(3):303-307, 1997.
38. Menke V, Van Es JH, De Lau W, Van Den Born M, Kuipers EJ, Siersema PD, De Bruin RW, Kusters JG, Clevers H. Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Models Mechanisms 3(1-2):104-110, 2010.
39. Milano F, Van Baal JW, Buttar NS, Rygiel AM, De Kort F, Demars CJ, Rosmolen WD, Bergman JJ, Va M, Wang KK, Peppelenbosch MP, Krishnadath KK. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132(7):2412-2421, 2007.
40. Moyes LH, Mcewan H, Radulescu S, Pawlikowski J, Lamm CG, Nixon C, Sansom OJ, Going JJ, Fullarton GM, Adams PD. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus. J Pathol 228(1):99-112, 2012.
41. Mueller J, Werner M, Stolte M. Barrett's esophagus: histopathologic definitions and diagnostic criteria. World J Surg 28(2):148-154, 2004.
42. Nicholson AM, Graham TA, Simpson A, Humphries A, Burch N, Rodriguez-Justo M, Novelli M, Harrison R, Wright NA, Mcdonald SaC, Jankowski JA. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 61(10):1380-1389, 2012.
43. Orlando RC. Mucosal defense in Barrett's esophagus. In: Barrett's Esophagus and Esophageal Adenocarcinoma. pp 60-72. Blackwell Publishing Ltd., 2007.
44. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19(6):1468-1470, 2010.
45. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 105(1):98-100, 2003.
46. Quante M, Bhagat G, Abrams JA, Marache F, Good P, Lee MD, Lee Y, Friedman R, Asfaha S, Dubeykovskaya Z, Mahmood U, Figueiredo JL, Kitajewski J, Shawber C, Lightdale CJ, Rustgi AK, Wang TC. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer cell 21(1):36-51, 2012.
47. Que J, Choi M, Ziel JW, Klingensmith J, Hogan BL. Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation 74(7):422-437, 2006.
48. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 10(2):87-101, 2010.
49. Roberts DJ, Johnson RL, Burke AC, Nelson CE, Morgan BA, Tabin C. Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regionalization of the chick hindgut. Development 121(10):3163-3174, 1995.
50. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agreus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129(6):1825-1831, 2005.
51. Rugge M, Fassan M, Battaglia G, Parente P, Zaninotto G, Ancona E. Intestinal or gastric? The unsolved dilemma of Barrett's metaplasia. Hum Pathol 40(8):1206-1207; author reply 1207-1208, 2009.
52. Sarosi G, Brown G, Jaiswal K, Feagins LA, Lee E, Crook TW, Souza RF, Zou YS, Shay JW, Spechler SJ. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 21(1):43-50, 2008.
53. Seery JP. Stem cells of the oesophageal epithelium. J Cell Sci 115(Pt 9):1783-1789, 2002.
54. Seery JP, Watt FM. Asymmetric stem-cell divisions define the architecture of human oesophageal epithelium. Curr Biol 10(22):1447-1450, 2000.
55. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119(2):333-338, 2000.
56. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4(5):566-572, 2006.
57. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol 38(7):464-468, 2008.
58. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53(8):1070-1074, 2004.
59. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 138(3):854-869, 2010.
60. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 87(4):927-933, 1984.
61. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 140(3):e18-e52; quiz e13, 2011.
62. Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, Lynch JP, Rustgi AK. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PloS One 3(10):e3534, 2008.
63. Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S, Amano Y, Kinoshita Y. Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab Invest 92(6):896-909, 2012.
64. Thrift AP, Pandeya N, Smith KJ, Green AC, Hayward NK, Webb PM, Whiteman DC. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer 130(10):2407-2416, 2012.
65. Thrift AP, Pandeya N, Smith KJ, Mallitt KA, Green AC, Webb PM, Whiteman DC. Lifetime alcohol consumption and risk of Barrett's esophagus. Am J Gastroenterol 106(7):1220-1230, 2011.
66. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 23(12):3155-3162, 2012.
67. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell Biol 3(3):187-194, 2002.
68. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111(5):1192-1199, 1996.
69. Van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, Van Deventer SJ, Wang KK, Peppelenbosch MP, Krishnadath KK. A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129(4):1274-1281, 2005.
70. Van Sandick JW, Van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43(2):216-222, 1998.
71. Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, Copeland NA, Harmon JW, Phillips WA, Watkins DN. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 138(5):1810-1822, 2010.
72. Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R, Vincent M, Lu X, Bellizzi AM, Ho KY, Crum CP, Xian W, McKeon F. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 145(7):1023-1035, 2011.
73. Westhoff B, Brotze S, Weston A, Mcelhinney C, Cherian R, Mayo MS, Smith HJ, Sharma P. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61(2):226-231, 2005.
74. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 57(2):173-180, 2008.
75. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3(9):676-684, 2003.
76. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92(1):118-124, 1987.
77. Wong NA, Wilding J, Bartlett S, Liu Y, Warren BF, Piris J, Maynard N, Marshall R, Bodmer WF. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A 102(21):7565-7570, 2005.
78. Yamanaka Y, Shiotani A, Fujimura Y, Ishii M, Fujita M, Matsumoto H, Tarumi K, Kamada T, Hata J, Haruma K. Expression of Sonic hedgehog (SHH) and CDX2 in the columnar epithelium of the lower oesophagus. Dig Liver Dis 43(1):54-59, 2011.
79. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 37(12):1359-1365, 2002.
80. Yu WY, Slack JM, Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol 284(1):157-170, 2005.